https://www.idival.org/wp-content/uploads/2022/05/cab-presentacion.jpg

Creation of the National Catalog of Health Sciences ISCIII

6 de January de 2019

The Marquesa de Pelayo Library, depends organically of IDIVAL, has participated in the design and implementation of the National Catalog of Health Sciences (CNCS) led by the National Library of Health Sciences, recently presented at the Madrid office of ISCIII. The catalog reflects the printed and electronic funds of all libraries specialized in Health Sciences […]

Read more →

MIRCAST a study in the european field leaded by IDIVAL and HUMV starts data recruitment in October

26 de October de 2018

      MIRCAST study is an international multicenter study led for all of participating centers from IDIVAL. The objective of this study is to evaluate the different ways of performing the intestinal anastomosis after the minimally invasive right colectomy and to determine if the robotic instruments have an added value in these procedures. MIRCAST […]

Read more →

IDIVAL receives the European certification of human resources HRS4R

20 de October de 2018

IDIVAL has just received the award of excellence in human resources known as HRS4R. This seal implies recognition by the Euraxess of compliance with European standards in human resources management in research by IDIVAL. To obtain it, a team composed of researchers and management personnel has carried out an analysis of the situation of the […]

Read more →

Second Tichron project meeting led by the SCS and IDIVAL

20 de September de 2018

The meeting, arranged by the French partners, it will be held in Purpan, Toulouse, in the Paule de Viguier University Hospital, the days 15th and 16th of October.  This meeting will be useful for all partners, ACCOMIP (France), MEDES (France), Minho’s University (Portugal), FUTURE BALLONS (Portugal), CTIC (Spain) and the SCS with IDIVAL as leaders, […]

Read more →

Researchers of IDIVALs microbiology and infectious diseases group

14 de May de 2018

This article collects the work of the doctoral thesis of Sana Alibí, from Sousse (Tunisia), co-directed by Jesús Navas Méndez, professor of the Department of Molecular Biology at the University of Cantabria and researcher of the Microbiology and Infectious Diseases group of IDIVAL, and Jalel Boukadida, head of the Microbiology service of the Sousse hospital. […]

Read more →

Valdecilla brand exceeds 120000 references in international literature

13 de February de 2018

Valdecilla brand, created in 1929, has been cited more than 120,000 times by the international biomedical literature, according to data obtained on the Web of Science database. According to these data, papers published by the authors who have in their affiliation the brand Valdecilla (exclusive brand worldwide of our Hospital) have been referenced in more […]

Read more →

Project Small World Initiative SWI

31 de January de 2018

Three schools, Sagrado Corazón (Esclavas), La Salle and La Marina in Bezana, have completed the first phase of the SWI project that IDIVAL carries out in Cantabria. The project involves involving pre-university students (Secondary and high school) in a real research project, aimed at solving one of the most serious human health problems we face: […]

Read more →

Evolutionary study 11C-PIB and 18F-FDG PET CT

The Health Institute Carlos III has funded the project “Evolutionary study at 5 years in a population with mild cognitive impairment (MCI) previously evaluated with 11C-PIB and 18F-FDG PET / CT” in the call Health Strategic Action 2016, PI 16/01656. The project is led by Dr. Julio Jiménez-Bonilla, Facultative of the Nuclear Medicine Service of […]

Read more →

IDIVAL creates a brain bank

19 de November de 2017

Marqués de Valdecilla University Hospital and the Biomedical Research Institute (IDIVAL) have set in motion a brain bank to collect, process, store and transfer biological samples donated by patients and individuals without neurological pathology to be used in research projects. This brain bank is coordinated by Dr. Nuria Terán, from the Pathological Anatomy Unit, and […]

Read more →

Complete response under sorafenib in patients with hepatocellular carcinoma

1 de November de 2017

Sorafenib is the principal (and until recently the only) first-line systemic treatment for patients with advanced hepatocellular carcinoma (HCC). Despite having been shown to improve survival in 2 randomized clinical trials compared with placebo [Llovet JM et al. N Engl J Med. 2008; 359: 378-90 and Chen A-L et al. Lancet Oncol. 2009; 10: 25-34] […]

Read more →